ADMA Biologics, Inc. (NASDAQ:ADMA – Get Free Report) Director Jerrold B. Grossman purchased 130,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were bought at an average price of $3.71 per share, with a total value of $482,300.00. Following the completion of the transaction, the director now owns 443,265 shares of the company’s stock, valued at $1,644,513.15. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
ADMA Biologics Price Performance
Shares of ADMA opened at $3.89 on Friday. ADMA Biologics, Inc. has a fifty-two week low of $2.24 and a fifty-two week high of $4.65. The firm’s 50 day moving average price is $3.90 and its 200 day moving average price is $3.69. The company has a market cap of $874.88 million, a P/E ratio of -19.45 and a beta of 0.79. The company has a quick ratio of 2.49, a current ratio of 6.35 and a debt-to-equity ratio of 1.03.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). ADMA Biologics had a negative net margin of 19.36% and a negative return on equity of 27.55%. The firm had revenue of $60.12 million for the quarter, compared to the consensus estimate of $55.45 million. During the same period in the prior year, the firm earned ($0.07) EPS. On average, research analysts forecast that ADMA Biologics, Inc. will post -0.06 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ADMA Biologics
Wall Street Analysts Forecast Growth
ADMA has been the subject of a number of recent analyst reports. Mizuho lifted their price target on shares of ADMA Biologics from $6.00 to $7.00 in a research report on Thursday, August 10th. StockNews.com upgraded shares of ADMA Biologics from a “sell” rating to a “hold” rating in a research report on Saturday. Raymond James lifted their price target on shares of ADMA Biologics from $5.00 to $6.00 and gave the company a “strong-buy” rating in a research report on Thursday, August 10th. HC Wainwright lifted their price target on shares of ADMA Biologics from $4.50 to $5.00 and gave the company a “buy” rating in a research report on Thursday, August 10th. Finally, Cantor Fitzgerald lifted their price objective on shares of ADMA Biologics from $5.00 to $6.00 and gave the company an “overweight” rating in a report on Thursday, August 10th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $6.00.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
- Five stocks we like better than ADMA Biologics
- P/E Ratio Calculation: How to Assess Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Invest in EV Charging Stations
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.